Moderna MRNA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Contract with Customer, Liability by Product | ||||||
| Net product sales | $567M-62.8% | $626M-67.9% | $707M-70.2% | $1.01B-70.7% | $1.53B-65.3% | |
| Other revenue | $544M— | $412M— | $290M— | —— | —— | |
| Total Revenue by Product | ||||||
| Collaboration Arrangement, Including Arrangements With Affiliate | $17M-65.3% | $13M-72.9% | $25M-54.5% | $46M-19.3% | $49M-32.9% | |
| Grant revenue | $21M-89.2% | $22M-88.6% | $30M-83.6% | $23M-89.5% | $194M+169% | |
| Licensing and royalty revenue | $4M-92.0% | $12M-71.4% | $17M-54.1% | $22M-26.7% | $50M— | |
| Additions by Product | ||||||
| Net product sales | $108M-48.8% | $108M-52.0% | $85M-84.0% | $113M-80.7% | $211M-56.4% | |
| Other revenue | $251M— | $212M— | —— | —— | —— | |
| Contract With Customer, Liability, Deductions During Period by Product | ||||||
| Net product sales | $167M-73.8% | $189M-70.9% | $384M-75.7% | $632M-58.2% | $637M-63.0% | |
| Other revenue | $119M— | $90M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Moderna break its business down?
- Moderna (MRNA) reports contract with customer, liability by product across 2 parts — Net product sales and Other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Moderna's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Moderna's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
